Clinical Trial Results:
A Randomized Open Label Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function after Colorectal Surgery
Summary
|
|
EudraCT number |
2013-005327-16 |
Trial protocol |
GB |
Global end of trial date |
01 Jul 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Jul 2020
|
First version publication date |
29 Jul 2020
|
Other versions |
|
Summary report(s) |
Targinact |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NA
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02109640 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Clintrials.gov Number: NCT02109640, REC Number: 14/ES/0016 | ||
Sponsors
|
|||
Sponsor organisation name |
University of Edinburgh & NHS Lothian
|
||
Sponsor organisation address |
47 Little France Crescent, Edinburgh, United Kingdom, EH16 4TJ
|
||
Public contact |
Hugh Paterson, University of Edinburgh, 07780 957402, hugh.paterson@ed.ac.uk
|
||
Scientific contact |
Hugh Paterson, University of Edinburgh, 07780 957402, hugh.paterson@ed.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Jul 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Sep 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Jul 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of the study was to compare Targinact (prolonged release naloxone + oxycodone) with current standard treatment (oxycodone alone) in post-operative return of normal gut function after elective colorectal resectional surgery.
|
||
Protection of trial subjects |
As with all opioid analgesics, there is a risk of side effects. Initial doses of the study drug were given in hospital under regular monitoring of observations as per normal practice in post-operative patients. Participants discharged on study drug were counselled on the risks of opioid analgesics as per normal practice and advised to discontinue use at the earliest opportunity.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
10 Dec 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 62
|
||
Worldwide total number of subjects |
62
|
||
EEA total number of subjects |
62
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
14
|
||
From 65 to 84 years |
46
|
||
85 years and over |
2
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Patients scheduled for elective laparoscopic segmental colonic resection in a single colorectal surgery unit were recruited by study staff during scheduled preoperative visits. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Patients scheduled for elective laparoscopic segmental colonic resection in a single colorectal surgery unit were screened for eligibility. 82 patients were assessed for eligibility. 20 of these were excluded: did not meet inclusion criteria n = 16; declined to participate n = 2; other reason n = 2. 62 patients were recruited. | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Whole study period (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Blinding implementation details |
The statistician was blinded to which group was allocated to intervention and which to control.
|
||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Oxycodone | ||||||||||||||||||||||||
Arm description |
Post-op analgesia based on modified release oxycodone | ||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||
Investigational medicinal product name |
Oxycodone
|
||||||||||||||||||||||||
Investigational medicinal product code |
PL 16950/0097-0100,0123,0139-0141, 0150
|
||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
5-20mgd bd
|
||||||||||||||||||||||||
Arm title
|
Targinact | ||||||||||||||||||||||||
Arm description |
Intervention arm | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Targinact
|
||||||||||||||||||||||||
Investigational medicinal product code |
PRD506871
|
||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
5-20mg bd
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Oxycodone
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Post-op analgesia based on modified release oxycodone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Targinact
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Intervention arm | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Subjects receiving the intervention/control
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Analyses of the data included Fisher’s exact test for categorical data (owing to the small numbers in some of the cells), and Student’s t test, with log transformation where appropriate. Estimates of differences in proportions and means were also calculated. The randomized groups were compared for a number of clinical measures, and in general a comment is made where there was little or no difference between the groups.
All of the analyses are descriptive, no adjustment was made for multiple comparisons.
A two-sided 5 per cent significance level was applied throughout.
Participant data was anonymised prior to analysis and the analysis was conducted by an independent statistician who was blinded to the treatment.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Oxycodone
|
||
Reporting group description |
Post-op analgesia based on modified release oxycodone | ||
Reporting group title |
Targinact
|
||
Reporting group description |
Intervention arm | ||
Subject analysis set title |
Subjects receiving the intervention/control
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Analyses of the data included Fisher’s exact test for categorical data (owing to the small numbers in some of the cells), and Student’s t test, with log transformation where appropriate. Estimates of differences in proportions and means were also calculated. The randomized groups were compared for a number of clinical measures, and in general a comment is made where there was little or no difference between the groups.
All of the analyses are descriptive, no adjustment was made for multiple comparisons.
A two-sided 5 per cent significance level was applied throughout.
Participant data was anonymised prior to analysis and the analysis was conducted by an independent statistician who was blinded to the treatment.
|
|
|||||||||||||||||||
End point title |
Return of postoperative gut function | ||||||||||||||||||
End point description |
Post-operative at which composite of the following achieved: tolerating oral diet; passage of flatus/faeces/minimal nausea and vomiting
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Assessed on postoperative day 3
|
||||||||||||||||||
|
|||||||||||||||||||
Attachments |
Postoperative day of return of gut function |
||||||||||||||||||
Statistical analysis title |
Return of gut function day 3 | ||||||||||||||||||
Comparison groups |
Oxycodone v Targinact
|
||||||||||||||||||
Number of subjects included in analysis |
50
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.264 [1] | ||||||||||||||||||
Method |
Fisher exact | ||||||||||||||||||
Parameter type |
Absolute % difference | ||||||||||||||||||
Point estimate |
17.1
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-10 | ||||||||||||||||||
upper limit |
40.7 | ||||||||||||||||||
Notes [1] - unadjusted |
|
|||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
30 days after operation
|
||||||||||||||||||||||||||||
Adverse event reporting additional description |
Normal postoperative events such as mild nausea, pain etc excluded a priori
|
||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||
Dictionary version |
19.1
|
||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||
Reporting group title |
Complications
|
||||||||||||||||||||||||||||
Reporting group description |
There were two major complications in the intervention arm of the study: one intra-abdominal collection was drained percutaneously and one (day 4) anastomotic dehiscence required reoperation, repair and proximal diversion. There were no major complications in the control arm. | ||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
05 Jun 2014 |
Change of study design from double-blinded to open label blinded design.
Addition of a novel method of documenting nutritional intake (Digital Photography of Food Method).
Addition of postoperative in-patient activity monitoring. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/27762434 |